AnaptysBio Valuation Multiples

AnaptysBio Overview

About AnaptysBio

AnaptysBio Inc is a clinical-stage biotechnology company. The company is focused on developing antibody product candidates for unmet medical needs in inflammation and immuno-oncology. The company is developing immune cell modulating antibodies, including two wholly owned checkpoint agonists in clinical-stage development, for autoimmune and inflammatory diseases; rosnilimab, PD-1 agonist in a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis (RA) and a Phase 2 trial for the treatment of moderate-to-severe ulcerative colitis (UC); and ANB032, BTLA agonist, in a Phase 2b trial for the treatment of moderate-to-severe atopic dermatitis (AD).

Founded

2005

HQ

Employees

136

Website

anaptysbio.com

Sectors

BiopharmaceuticalsBioTech

Financials (LTM)

Revenue: $209M

EBITDA: $29M

EV

$1B

Valuation Multiples

Multiples.vc

Start free trial

AnaptysBio Financials

AnaptysBio reported last 12-month revenue of $209M and EBITDA of $29M.

In the same LTM period, AnaptysBio generated $209M in gross profit, $29M in EBITDA, and had net loss of ($39M).

AnaptysBio P&L

In the most recent fiscal year, AnaptysBio reported revenue of $235M and EBITDA of $69M.

AnaptysBio expects next 12-month revenue of XXX and NTM EBITDA of XXX

AnaptysBio Stock Performance

AnaptysBio has current market cap of $2B, and enterprise value of $1B.

AnaptysBio's stock price is $60.56.

AnaptysBio Valuation Multiples

AnaptysBio trades at 6.9x EV/Revenue multiple, and 50.2x EV/EBITDA.

AnaptysBio Financial Valuation Multiples

As of March 18, 2026, AnaptysBio has market cap of $2B and EV of $1B.

Equity research analysts estimate AnaptysBio's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX

AnaptysBio has a P/E ratio of (42.8x).

AnaptysBio Margins & Growth Rates

AnaptysBio's revenue in the last 12 month declined by (42%).

AnaptysBio's revenue per employee in the last FY averaged $1.5M.

AnaptysBio's rule of 40 is (28%) (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).

AnaptysBio's rule of X is (91%) (created by Bessemer, rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).

AnaptysBio Public Comps

See public comps and valuation multiples for other Biopharmaceuticals comps.

AnaptysBio M&A Activity

AnaptysBio acquired XXX companies to date.

Last acquisition by AnaptysBio was on XXXXXXXX, XXXXX. AnaptysBio acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).

AnaptysBio Investment Activity

AnaptysBio invested in XXX companies to date.

AnaptysBio made its latest investment on XXXXXXXX, XXXXX. AnaptysBio invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).